Stateside boost to Relenza orders
The United States Department of Health and Human Services (HHS) has stated that it will increase its stockpile of the anti-viral treatment Relenza by 12.3 million courses.
The United States Department of Health and Human Services (HHS) has stated that it will increase its stockpile of the anti-viral treatment Relenza by 12.3 million courses.
The HHS intends to have a stockpile of 81 million courses of the drug by the completion date, December 2008. By December 2006 HHS will have a stockpile of 26 million courses of Relenza.
Peter Cook, CEO of the Australian pharmaceutical firm Biota who develop and manufacture Relenza, described the additional orders as "welcome news".